Free Trial
NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

Assembly Biosciences logo
$26.82 +1.32 (+5.18%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$25.91 -0.91 (-3.39%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Assembly Biosciences Stock (NASDAQ:ASMB)

Advanced

Key Stats

Today's Range
$23.84
$27.17
50-Day Range
$18.40
$26.93
52-Week Range
$7.75
$27.17
Volume
192,878 shs
Average Volume
149,921 shs
Market Capitalization
$205.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.25
Consensus Rating
Moderate Buy

Company Overview

Assembly Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ASMB MarketRank™: 

Assembly Biosciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 269th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Assembly Biosciences has a consensus price target of $41.25, representing about 53.8% upside from its current price of $26.82.

  • Amount of Analyst Coverage

    Assembly Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Assembly Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Assembly Biosciences is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Assembly Biosciences is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Assembly Biosciences has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Assembly Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    10.25% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 17.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Assembly Biosciences does not currently pay a dividend.

  • Dividend Growth

    Assembly Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.25% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 17.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Assembly Biosciences has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Assembly Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Assembly Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of Assembly Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 19.92% of the stock of Assembly Biosciences is held by institutions.

  • Read more about Assembly Biosciences' insider trading history.
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ASMB Stock News Headlines

Too busy for AI trading?
Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a single day. AMD jumped over 6%. But what if you didn’t need to chase the news?tc pixel
Guggenheim Remains a Buy on Assembly Biosciences (ASMB)
See More Headlines

ASMB Stock Analysis - Frequently Asked Questions

Assembly Biosciences' stock was trading at $15.78 at the start of the year. Since then, ASMB shares have increased by 70.0% and is now trading at $26.82.

Assembly Biosciences, Inc. (NASDAQ:ASMB) released its quarterly earnings data on Wednesday, August, 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping analysts' consensus estimates of ($1.73) by $0.40. The biopharmaceutical company earned $9.63 million during the quarter, compared to analysts' expectations of $5.30 million. Assembly Biosciences had a negative net margin of 117.20% and a negative trailing twelve-month return on equity of 149.01%.

Assembly Biosciences's stock reverse split on Monday, February 12th 2024.The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/06/2025
Today
10/09/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ASMB
CIK
1426800
Employees
100
Year Founded
2005

Price Target and Rating

High Price Target
$50.00
Low Price Target
$38.00
Potential Upside/Downside
+53.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.18 million
Net Margins
-117.20%
Pretax Margin
-117.42%
Return on Equity
-149.01%
Return on Assets
-39.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.64
Quick Ratio
1.64

Sales & Book Value

Annual Sales
$28.52 million
Price / Sales
7.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.25 per share
Price / Book
5.11

Miscellaneous

Outstanding Shares
7,670,000
Free Float
7,265,000
Market Cap
$205.71 million
Optionable
Optionable
Beta
0.60

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ASMB) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners